21353695

Source:http://linkedlifedata.com/resource/pubmed/id/21353695

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0013072, umls-concept:C0025266, umls-concept:C0257685, umls-concept:C0280855, umls-concept:C0376358, umls-concept:C1690432
pubmed:issue	9768
pubmed:dateCreated	2011-3-7
pubmed:databankReference	http://linkedlifedata.com/resource/pubmed/xref/ClinicalTrials.gov/NCT00321620
pubmed:abstractText	Bone metastases are a major burden in men with advanced prostate cancer. We compared denosumab, a human monoclonal antibody against RANKL, with zoledronic acid for prevention of skeletal-related events in men with bone metastases from castration-resistant prostate cancer.
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/K24 CA121990-03, http://linkedlifedata.com/resource/pubmed/grant/K24 CA121990-04, http://linkedlifedata.com/resource/pubmed/grant/K24 CA121990-05
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/21353695-12359855, http://linkedlifedata.com/resource/pubmed/commentcorrection/21353695-12520558, http://linkedlifedata.com/resource/pubmed/commentcorrection/21353695-12548589, http://linkedlifedata.com/resource/pubmed/commentcorrection/21353695-12748652, http://linkedlifedata.com/resource/pubmed/commentcorrection/21353695-12855635, http://linkedlifedata.com/resource/pubmed/commentcorrection/21353695-14581438, http://linkedlifedata.com/resource/pubmed/commentcorrection/21353695-14633717, http://linkedlifedata.com/resource/pubmed/commentcorrection/21353695-15173273, http://linkedlifedata.com/resource/pubmed/commentcorrection/21353695-15632381, http://linkedlifedata.com/resource/pubmed/commentcorrection/21353695-17450591, http://linkedlifedata.com/resource/pubmed/commentcorrection/21353695-17544845, http://linkedlifedata.com/resource/pubmed/commentcorrection/21353695-17785705, http://linkedlifedata.com/resource/pubmed/commentcorrection/21353695-18045781, http://linkedlifedata.com/resource/pubmed/commentcorrection/21353695-18061356, http://linkedlifedata.com/resource/pubmed/commentcorrection/21353695-18309951, http://linkedlifedata.com/resource/pubmed/commentcorrection/21353695-18602738, http://linkedlifedata.com/resource/pubmed/commentcorrection/21353695-18639279, http://linkedlifedata.com/resource/pubmed/commentcorrection/21353695-18725648, http://linkedlifedata.com/resource/pubmed/commentcorrection/21353695-19042080, http://linkedlifedata.com/resource/pubmed/commentcorrection/21353695-19237632, http://linkedlifedata.com/resource/pubmed/commentcorrection/21353695-19364971, http://linkedlifedata.com/resource/pubmed/commentcorrection/21353695-19671656, http://linkedlifedata.com/resource/pubmed/commentcorrection/21353695-19674936, http://linkedlifedata.com/resource/pubmed/commentcorrection/21353695-20116997, http://linkedlifedata.com/resource/pubmed/commentcorrection/21353695-20353536, http://linkedlifedata.com/resource/pubmed/commentcorrection/21353695-20610543, http://linkedlifedata.com/resource/pubmed/commentcorrection/21353695-20621630, http://linkedlifedata.com/resource/pubmed/commentcorrection/21353695-21060033, http://linkedlifedata.com/resource/pubmed/commentcorrection/21353695-21353698, http://linkedlifedata.com/resource/pubmed/commentcorrection/21353695-21499282, http://linkedlifedata.com/resource/pubmed/commentcorrection/21353695-3102281
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/2985213R
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Bone Density Conservation Agents, http://linkedlifedata.com/resource/pubmed/chemical/Diphosphonates, http://linkedlifedata.com/resource/pubmed/chemical/Imidazoles, http://linkedlifedata.com/resource/pubmed/chemical/RANK Ligand, http://linkedlifedata.com/resource/pubmed/chemical/denosumab, http://linkedlifedata.com/resource/pubmed/chemical/zoledronic acid
pubmed:status	MEDLINE
pubmed:month	Mar
pubmed:issn	1474-547X
pubmed:author	pubmed-author:BrownJanetJ, pubmed-author:CarducciMichaelM, pubmed-author:DamiãoRonaldoR, pubmed-author:DanseyRogerR, pubmed-author:FizaziKarimK, pubmed-author:GoesslCarstenC, pubmed-author:JiangQiQ, pubmed-author:KarshLawrenceL, pubmed-author:MileckiPiotrP, pubmed-author:RaderMichaelM, pubmed-author:ShoreNealN, pubmed-author:SmithMatthewM, pubmed-author:TadrosSylviaS, pubmed-author:WangHueiH
pubmed:copyrightInfo	Copyright © 2011 Elsevier Ltd. All rights reserved.
pubmed:issnType	Electronic
pubmed:day	5
pubmed:volume	377
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	813-22
pubmed:dateRevised	2011-9-26
pubmed:meshHeading	pubmed-meshheading:21353695-Aged, pubmed-meshheading:21353695-Antibodies, Monoclonal, pubmed-meshheading:21353695-Bone Density Conservation Agents, pubmed-meshheading:21353695-Bone Neoplasms, pubmed-meshheading:21353695-Diphosphonates, pubmed-meshheading:21353695-Humans, pubmed-meshheading:21353695-Imidazoles, pubmed-meshheading:21353695-Male, pubmed-meshheading:21353695-Middle Aged, pubmed-meshheading:21353695-Orchiectomy, pubmed-meshheading:21353695-Prostatic Neoplasms, pubmed-meshheading:21353695-RANK Ligand
pubmed:year	2011
pubmed:articleTitle	Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
pubmed:affiliation	Institut Gustave Roussy, University of Paris Sud, Villejuif, France. fizazi@igr.fr
pubmed:publicationType	Journal Article, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study

More...